How to cite item

New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?

   
@article{ATM26472,
	author = {Markus Eckstein and Shilpa Gupta},
	title = {New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?},
	journal = {Annals of Translational Medicine},
	volume = {7},
	number = {Suppl 3},
	year = {2019},
	keywords = {},
	abstract = {Checkpoint inhibitors such as Pembrolizumab (Keytruda®, MSD), Atezolizumab (Tecentriq®, Roche), Durvalumab (Imfinzi®, AstraZeneca) or Nivolumab (Opdivo®, BMS) have significantly improved curative and palliative treatment of solid malignancies (1-4). However, clinical responses vary largely across different tumor entities. Since the currently used standard predictive tool—PD-L1 assessment by immunohistochemistry—shows largely varying predictive efficacy in different tumor types, e.g., in urothelial cancer (5-7), there is a heavy need for additional complementary biomarkers which can improve the current immunotherapy selection and prediction of therapy success.},
	issn = {2305-5847},	url = {https://atm.amegroups.org/article/view/26472}
}